<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "journalpublishing3.dtd">
<article xml:lang="en" article-type="research-article" xmlns:xlink="http://www.w3.org/1999/xlink">
<?release-delay 0|0?>
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">ETM</journal-id>
<journal-title-group>
<journal-title>Experimental and Therapeutic Medicine</journal-title>
</journal-title-group>
<issn pub-type="ppub">1792-0981</issn>
<issn pub-type="epub">1792-1015</issn>
<publisher>
<publisher-name>D.A. Spandidos</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3892/etm.2019.7757</article-id>
<article-id pub-id-type="publisher-id">ETM-0-0-7757</article-id>
<article-categories>
<subj-group>
<subject>Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Function and mechanism of pyrin and IL-10 in the regulation of the inflammasome in pulmonary vascular endothelial cells following hemorrhagic shock</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author"><name><surname>Jin</surname><given-names>Xin</given-names></name>
<xref rid="af1-etm-0-0-7757" ref-type="aff">1</xref>
<xref rid="af2-etm-0-0-7757" ref-type="aff">2</xref></contrib>
<contrib contrib-type="author"><name><surname>Yao</surname><given-names>Yongxing</given-names></name>
<xref rid="af1-etm-0-0-7757" ref-type="aff">1</xref></contrib>
<contrib contrib-type="author"><name><surname>Lu</surname><given-names>Xing</given-names></name>
<xref rid="af2-etm-0-0-7757" ref-type="aff">2</xref></contrib>
<contrib contrib-type="author"><name><surname>Xu</surname><given-names>Peng</given-names></name>
<xref rid="af2-etm-0-0-7757" ref-type="aff">2</xref></contrib>
<contrib contrib-type="author"><name><surname>Xia</surname><given-names>Yanfei</given-names></name>
<xref rid="af2-etm-0-0-7757" ref-type="aff">2</xref>
<xref rid="c1-etm-0-0-7757" ref-type="corresp"/></contrib>
<contrib contrib-type="author"><name><surname>Zhu</surname><given-names>Shengmei</given-names></name>
<xref rid="af1-etm-0-0-7757" ref-type="aff">1</xref>
<xref rid="c2-etm-0-0-7757" ref-type="corresp"/></contrib>
</contrib-group>
<aff id="af1-etm-0-0-7757"><label>1</label>Department of Anesthesia, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310003, P.R. China</aff>
<aff id="af2-etm-0-0-7757"><label>2</label>Department of Anesthesia, Zhejiang Hospital, Hangzhou, Zhejiang 310013, P.R. China</aff>
<author-notes>
<corresp id="c1-etm-0-0-7757"><italic>Correspondence to</italic>: Professor Yanfei Xia, Department of Anesthesia, Zhejiang Hospital, 12 Lingyin Road, Hangzhou, Zhejiang 310013, P.R. China, E-mail: <email>xiayf0303@126.com</email></corresp>
<corresp id="c2-etm-0-0-7757">Dr Shengmei Zhu, Department of Anesthesia, First Affiliated Hospital, Zhejiang University School of Medicine, 79 Qingchun Road, Hangzhou, Zhejiang 310003, P.R. China, E-mail: <email>smzhu20088@zju.edu.cn</email></corresp>
</author-notes>
<pub-date pub-type="ppub">
<month>09</month>
<year>2019</year></pub-date>
<pub-date pub-type="epub">
<day>09</day>
<month>07</month>
<year>2019</year></pub-date>
<volume>18</volume>
<issue>3</issue>
<fpage>1768</fpage>
<lpage>1774</lpage>
<history>
<date date-type="received"><day>07</day><month>05</month><year>2018</year></date>
<date date-type="accepted"><day>23</day><month>05</month><year>2019</year></date>
</history>
<permissions>
<copyright-statement>Copyright: &#x00A9; Jin et al.</copyright-statement>
<copyright-year>2019</copyright-year>
<license license-type="open-access">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-NonCommercial-NoDerivs License</ext-link>, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.</license-p></license>
</permissions>
<abstract>
<p>The present study aimed to evaluate the function of pyrin and interleukin-10 (IL-10) and the potential mechanisms underlying the regulation of inflammation in pulmonary vascular endothelial cells (ECs) following hemorrhagic shock (HS). Adult female Sprague-Dawley rats were divided into 4 groups (n=6 in each group) to examine the changes in pyrin expression following HS-lipopolysaccharide (LPS) administration, including the following groups: A sham operation (SM) &#x002B; tracheal injection of saline (SAL) group; a HS &#x002B; SAL group; a SM &#x002B; LPS group (with a tracheal injection of endotoxin); and a HS &#x002B; LPS group. An additional 4 groups were used to evaluate the function of IL-10, by the additional intratracheal injection of recombinant IL-10. Western blot analysis and immunofluorescence were performed in order to investigate the changes to pyrin and IL-10 expression in pulmonary vascular ECs. The expression levels of pyrin in the SM &#x002B; LPS group were significantly increased in comparison with the SM &#x002B; SAL group (P&#x003C;0.01). Additionally, the expression levels of pyrin were significantly increased in the HS &#x002B; LPS group compared with the HS &#x002B; SAL group (P&#x003C;0.01). The expression levels of caspase-1 were significantly increased in the HS &#x002B; LPS group compared with those in the other three groups (P&#x003C;0.01). The expression levels of pyrin in the HS &#x002B; LPS &#x002B; IL-10 group were significantly increased compared with the HS &#x002B; LPS group (P&#x003C;0.01). The expression levels of caspase-1 were significantly decreased following IL-10 treatment compared with those in the HS &#x002B; LPS group (P&#x003C;0.01). Therefore, HS attenuated LPS-induced pyrin expression in pulmonary vascular ECs and may also inhibit the expression of IL-10, resulting in the activation of caspase-1 subsequent to a second LPS insult.</p>
</abstract>
<kwd-group>
<kwd>hemorrhagic shock</kwd>
<kwd>pulmonary vascular endothelial cells</kwd>
<kwd>interleukin-10</kwd>
<kwd>pyrin</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec sec-type="intro">
<title>Introduction</title>
<p>Hemorrhagic shock (HS) and subsequent resuscitation result in an overly active systemic immuno-inflammatory response that may produce an exaggerated physiological response, resulting in systemic inflammatory response syndrome (SIRS). Complications of SIRS often involve organ dysfunction and organ failure, including acute lung injury (ALI) and multiple organ dysfunction syndrome (MODS), with high mortality rates, ranging from 27&#x2013;100&#x0025; (<xref rid="b1-etm-0-0-7757" ref-type="bibr">1</xref>,<xref rid="b2-etm-0-0-7757" ref-type="bibr">2</xref>). Although substantial progress has been made in the treatment of HS, the incidence of SIRS following HS remains up to 43&#x0025; (<xref rid="b3-etm-0-0-7757" ref-type="bibr">3</xref>), and there is no effective measure to prevent the patients from entering the SIRS-MODS stage.</p>
<p>The &#x2018;second hit&#x2019; model proposed by Moore <italic>et al</italic> (<xref rid="b4-etm-0-0-7757" ref-type="bibr">4</xref>) is considered to be a good standard as an empirical explanation for HS-associated inflammation. HS, the first &#x2018;hit&#x2019; primes the inflammatory system and a second &#x2018;hit&#x2019;, for example through infection, aggravates the already sensitized immune system (<xref rid="b4-etm-0-0-7757" ref-type="bibr">4</xref>). Inflammation is governed by interactions between proinflammatory and counter-inflammatory states; the imbalance between pro-inflammatory and anti-inflammatory responses serves a key role in the development of ALI and MODS (<xref rid="b5-etm-0-0-7757" ref-type="bibr">5</xref>), but the exact mechanism of HS sensitization to ALI and SIRS remains unclear. Therefore, it is of vital importance to investigate the mechanisms involved in the inflammatory response state following HS.</p>
<p>Evidence has revealed that the activation of pulmonary vascular endothelial cells (ECs) and EC-mediated inflammation serve important functions in organ injury following a hemorrhage (<xref rid="b6-etm-0-0-7757" ref-type="bibr">6</xref>). The pyrin protein, consisting of 781 amino acid residues, is expressed in neutrophils, monocytes and macrophages, and its expression is regulated by a variety of cytokines (<xref rid="b7-etm-0-0-7757" ref-type="bibr">7</xref>). The pyrin protein is able to inhibit the activation of caspase-1 and inhibit the mature release of interleukin (IL)-1&#x03B2;, a proinflammatory mediator (<xref rid="b8-etm-0-0-7757" ref-type="bibr">8</xref>) that is involved in lung inflammation (<xref rid="b9-etm-0-0-7757" ref-type="bibr">9</xref>). Caspase-1 is also synthesized as an inactive 45 kDa protein (procaspase-1) that undergoes autocatalytic processing following assembly of the inflammasome in response to an appropriate stimulus (<xref rid="b10-etm-0-0-7757" ref-type="bibr">10</xref>,<xref rid="b11-etm-0-0-7757" ref-type="bibr">11</xref>). Of the cytokines that are able to regulate the expression of pyrin, interleukin (IL)-10 is able to induce the expression of pyrin protein in macrophages (<xref rid="b8-etm-0-0-7757" ref-type="bibr">8</xref>). It has been demonstrated that the immunosuppressive cytokine IL-10 may inhibit the activation of monocytes/macrophages and decrease the release of cytokines and chemokines induced by lipopolysaccharides (LPS) (<xref rid="b9-etm-0-0-7757" ref-type="bibr">9</xref>). <italic>In vivo</italic> experiments of ischemia/reperfusion have revealed that IL-10 is able to effectively decrease structural organ damage; however, when a IL-10 neutralizing antibody or IL-10 knockout is used, the inflammatory reaction is aggravated (<xref rid="b12-etm-0-0-7757" ref-type="bibr">12</xref>).</p>
<p>Taking into consideration these diverse results, it was hypothesized that pyrin and IL-10 are involved in the regulation of inflammation in pulmonary vascular ECs, and that the decrease in IL-10 expression contributes to a severe inflammatory response.</p>
</sec>
<sec sec-type="materials|methods">
<title>Materials and methods</title>
<sec>
<title/>
<sec>
<title>Animals</title>
<p>Adult female Sprague-Dawley rats (n=100; weight, 200&#x2013;240 g; Zhejiang Laboratory Animal Center) were provided by the Experimental Animal Center of the First Affiliated Hospital, Zhejiang University School of Medicine (Zhejiang, China). The rats were maintained in a standard cage, in a 22&#x2013;24&#x00B0;C environment, with a 12:12 h light:dark cycle and <italic>ad libitum</italic> access to food and water. All experiments were performed in accordance with the institutional guidelines for animal care and welfare. The present study was approved by the Medical Ethics Committee of Zheijang Hospital.</p>
</sec>
<sec>
<title>Experimental protocol</title>
<p>Prior to the initiation of the experiment, the rats were fasted for 24 h with <italic>ad libitum</italic> access to water (<xref rid="b13-etm-0-0-7757" ref-type="bibr">13</xref>,<xref rid="b14-etm-0-0-7757" ref-type="bibr">14</xref>), in order to avoid backflow and aspiration when the trachea was intubated, and the greatest weight loss observed was 16g (~7&#x0025; of body weight). Following the induction of anesthesia with an intraperitoneal injection of 2&#x0025; sodium pentobarbital solution (50 mg/kg; Westang Biotechenology, Co., Ltd.), the left femoral artery was cannulated with an external infusion device to allow for the monitoring of mean arterial pressure, blood sampling and resuscitation. HS was initiated by the withdrawal of arterial blood and the mean arterial pressure reached 40&#x00B1;5 mmHg within 20 min. Blood was collected into a 10 ml heparinized syringe to prevent the blood from clotting. In order to exclude the effect of heparin on the experimental results, the control group was administered equal amounts of heparin through arterial catheterization. Subsequent to a hypotensive period of 1 h, autologous blood transfusion was performed and the same quantity of lactate solution was administered (<xref rid="b15-etm-0-0-7757" ref-type="bibr">15</xref>). Resuscitation was completed within 20 min. Following resuscitation, the catheters were removed and the artery was ligated to close the incision. The sham surgery (SM) group underwent femoral artery catheterization without blood loss. Following resuscitation for 2 h, the rats were administered LPS (cat. no., L2880; Sigma-Aldrich; Merck KGaA) at a dose of 100 &#x00B5;g/kg body weight (<xref rid="b16-etm-0-0-7757" ref-type="bibr">16</xref>,<xref rid="b17-etm-0-0-7757" ref-type="bibr">17</xref>), which was intratracheally injected as the second &#x2018;hit&#x2019; model of HS-LPS. During the entire experiment, all rats were under anesthesia.</p>
<p>The experiment was divided into two parts. The first part was used to confirm that pulmonary ECs participated in the inflammatory process subsequent to the second &#x2018;hit&#x2019; and confirm whether the LPS-mediated upregulation of pyrin expression was impaired following HS. The rats were divided into 4 groups (n=6 for each group), as follows: i) A SM &#x002B; tracheal injection of saline (SAL) group; this was the negative control group; ii) a HS &#x002B; SAL group; iii) a SM &#x002B; LPS group. with a tracheal injection of endotoxin; and iv) a HS &#x002B; LPS group. A total of 8 h after tracheal injection, the rats were euthanized by administering an overdose of sodium pentobarbital solution (200 mg/kg) followed by cervical dislocation. Alveolar lavage was performed, lung tissues were collected and stored in liquid nitrogen, and then western blot analysis and immunofluorescence were performed.</p>
<p>The second part was performed to clarify the potential mechanism of the inhibition of the LPS-mediated upregulation of pyrin expression following HS. Rats were divided into four groups, as follows: i) A SM &#x002B; LPS group; ii) a HS &#x002B; LPS group (negative control group); ii) a HS &#x002B; LPS &#x002B; intratracheal injection of saline (NS) group; and iv) a HS &#x002B; LPS &#x002B; IL-10, with an intratracheal injection of recombinant IL-10 (BioLegend, Inc.) group. A total of 8 h after tracheal injection, the rats were euthanized by administering an overdose of sodium pentobarbital solution (200 mg/kg) followed by cervical dislocation. Alveolar lavage was performed, lung tissues were collected and stored in liquid nitrogen, and then western blot analysis was performed.</p>
</sec>
<sec>
<title>Immunofluorescence</title>
<p>The lung tissues were fixed in 4&#x0025; paraformaldehyde at 4&#x00B0;C overnight. The lung tissue of each group was serially sliced into 4-&#x00B5;m thick slices, and then incubated with 5&#x0025; goat serum (Beyotime Institute of Biotechnology) at 22&#x00B0;C for 1 h. Lung tissues from each group were sliced into 2 sections, and each sample was incubated for 48 h at 4&#x00B0;C with cluster of differentiation (CD)34 mouse primary antibodies (cat. no., 60108-1-lg) and anti-pyrin rabbit primary antibodies (cat. no., 24280-1-AP; both 1:100; ProteinTech Group, Inc.) respectively. CD34, a cell surface sialomucin-like glycoprotein, is commonly used as a marker for identifying vascular ECs (<xref rid="b18-etm-0-0-7757" ref-type="bibr">18</xref>). Vascular ECs stained with CD34 exhibit a red color in the cytoplasm. PBS was used as blank control instead of the primary antibody. Subsequent to washing with PBS 3 times (3 min each), the slides were incubated with Cy3-conjugated goat anti-mouse immunoglobulin (Ig)G (cat. no., P0193) and FITC-conjugated goat anti-rabbit IgG (cat. no., P0186; both 1:100; Beyotime Institute of Biotechnology) for 1 h at room temperature. The staining method was performed according to the manufacturer&#x0027;s protocol of immunofluorescence kits (Immunol Fluorence Staining Kit with Cy3-Labeled Goat Anti-Mouse IgG and Immunol Fluorescence Staining Kit with FITC-Labeled Goat Anti-Rabbit IgG; both Beyotime Institute of Biotechnology). Images were obtained using a wide-field fluorescence microscope (Olympus X-cite 120; Olympus Corporation; magnification, &#x00D7;200).</p>
</sec>
<sec>
<title>Western blot analysis</title>
<p>Lung tissues of rats were homogenized on ice and lysed in lysis buffer which was prepared as follows: 10 mM Tris (pH 7.4), 5 mM EDTA, 150 mM NaCl, 10 mM NaF, 1&#x0025; Triton X-100, 1 mM Na<sub>3</sub>VO<sub>4</sub>, 20 mM PMSF, 10 &#x00B5;g/ml leupeptin and 10 &#x00B5;g/ml aprotinin. The tissue homogenate was centrifuged at 1,000 &#x00D7; g in an Eppendorf centrifuge (Eppendorf) at 4&#x00B0;C for 10 min, and then the protein content in the supernatants were quantified using the Bradford method. Proteins (30 &#x00B5;g/lane) for each sample were separated using 10&#x0025; SDS-PAGE gel and then transferred onto a polyvinylidene fluoride membrane. Subsequent to being blocked by 5&#x0025; non-fat milk for 1 h at 22&#x00B0;C and then for 24 h at 4&#x00B0;C, the membranes were incubated with the primary antibodies against pyrin (1:1,000; cat. no., 24280-1-AP; ProteinTech Group, Inc.) and caspase-1 (1:2,000; cat. no., ab188326; Abcam). The blots were then washed and incubated with horseradish peroxidase (HRP)-labeled goat anti-rabbit IgG (1:2,000; cat. no., A0208; Beyotime Institute of Biotechnology) and HRP-labeled goat anti-mouse IgG (1:2,000; cat. no., A0216; Beyotime Institute of Biotechnology) for 2 h at room temperature. Protein bands were then detected by enhanced chemiluminescence. A ChemiDoc MP System (Bio-Rad Laboratories, Inc., Hercules, CA, USA) was used to capture the protein bands and then Image Lab 5.0 software (Bio-Rad Laboratories, Inc.) was used to analyze the bands. GAPDH and pro-caspase-1 were used as loading controls. Molecular weight standards were used from commercial markers (Thermo Fisher Scientific Inc.).</p>
</sec>
<sec>
<title>Statistical analysis</title>
<p>SPSS v20.0 software (IBM Corp.) was applied for statistical analysis and the experiments were performed and repeated three times. Data are presented as the mean &#x00B1; standard error of the mean. Data were analyzed using one-way analysis of variance followed by a Student-Neuman-Keuls post hoc test. P&#x003C;0.05 was considered to indicate a statistically significant difference.</p>
</sec>
</sec>
</sec>
<sec sec-type="results">
<title>Results</title>
<sec>
<title/>
<sec>
<title>HS attenuates the LPS-induced pyrin expression in pulmonary vascular ECs</title>
<p>Subsequent to the removal of the majority of the macrophages following lung lavage, an analysis of the distribution of ECs and pyrin was performed. In immunofluorescence staining, cells stained with CD34 (red) were considered to be pulmonary vascular ECs. As presented in <xref rid="f1-etm-0-0-7757" ref-type="fig">Fig. 1</xref>, these CD34-positive cells presented a typical cobblestone-like morphology. Pyrin staining (green) demonstrated the presence of pyrin in ECs. The second <italic>&#x2018;</italic>hit<italic>&#x2019;</italic>, HS-LPS, substantially decreased the expression of pyrin protein in pulmonary vascular ECs. Furthermore, the expression of pyrin was evaluated in the supernatant of the lung homogenate (<xref rid="f2-etm-0-0-7757" ref-type="fig">Fig. 2A</xref>). No difference regarding the expression levels of pyrin between the SM &#x002B; SAL group and the HS &#x002B; SAL group was observed (P&#x003E;0.05). The expression levels of pyrin in the SM &#x002B; LPS group were significantly increased in comparison with that in the SM &#x002B; SAL group (P&#x003C;0.01), demonstrating that LPS stimulation had significantly increased the pyrin protein expression level in pulmonary vascular ECs. Additionally, the expression of pyrin was significantly increased in the HS &#x002B; LPS group compared with the HS &#x002B; SAL group (P&#x003C;0.01). However, the pyrin expression level in the HS &#x002B; LPS group was significantly decreased compared with that of the SM &#x002B; LPS group (P&#x003C;0.01), indicating that HS weakened the expression of pyrin induced by LPS.</p>
<p>As presented in <xref rid="f2-etm-0-0-7757" ref-type="fig">Fig. 2B</xref>, there was no significant difference with regard to the expression of caspase-1 in the SM &#x002B; SAL and HS &#x002B; SAL groups (P&#x003E;0.05). The expression of caspase-1 in the SM &#x002B; LPS was increased compared with that in the SM &#x002B; SAL group (P&#x003C;0.01), demonstrating that LPS stimulation increased the expression of caspase-1 protein in pulmonary vascular ECs. In addition, the expression of caspase-1 in the HS &#x002B; LPS group was significantly increased compared with that in the SM &#x002B; LPS group (P&#x003C;0.01). Collectively, HS augmented the LPS-induced caspase-1 expression.</p>
</sec>
<sec>
<title>Involvement of IL-10 in regulating pyrin expression changes in pulmonary vascular ECs following the second &#x2018;hit&#x2019; of HS-LPS</title>
<p>The expression of the pyrin protein is regulated by various cytokines, including IL-10 (<xref rid="b8-etm-0-0-7757" ref-type="bibr">8</xref>). The present study assessed the hypothesis that HS damaged the expression of IL-10, thereby affecting the expression of the pyrin protein, which resulted in the activation of caspase-1 subsequent to the second <italic>&#x2018;</italic>hit<italic>&#x2019;</italic> of HS-LPS. As presented in <xref rid="f3-etm-0-0-7757" ref-type="fig">Fig. 3A</xref>, the expression levels of pyrin in the SM &#x002B; LPS group were significantly increased in comparison with the HS &#x002B; LPS group (P&#x003C;0.01); and the expression levels of pyrin in the HS &#x002B; LPS &#x002B; IL-10 group were significantly increased compared with the HS &#x002B; LPS group (P&#x003C;0.01). The results demonstrated that HS and the intratracheal injection of LPS may result in the expression of pyrin being significantly decreased, however, exogenous IL-10 treatment increases pyrin expression.</p>
<p>As presented in <xref rid="f3-etm-0-0-7757" ref-type="fig">Fig. 3B</xref>, the expression levels of cleaved caspase-1 were significantly different between the SM &#x002B; LPS and HS &#x002B; LPS groups (P&#x003C;0.01). The expression of caspase-1 was significantly decreased subsequent to IL-10 treatment compared with those in the HS &#x002B; LPS group (P&#x003C;0.01). Although HS promoted the LPS-induced caspase-1 expression, intratracheal IL-10 treatment may decrease the expression of caspase-1, alleviating the inflammatory reaction. Therefore, the IL-10 treatment-inhibited caspase-1 activation induced by LPS may occur through the upregulation of pyrin expression in HS rats.</p>
</sec>
</sec>
</sec>
<sec sec-type="discussion">
<title>Discussion</title>
<p>Systemic inflammatory response and organ failure are the primary factors affecting mortality in patients with HS and trauma. How HS enhances the inflammatory response of the body remains unclear. The activation of caspase-1 serves an important role in systemic inflammatory responses subsequent to shock (<xref rid="b10-etm-0-0-7757" ref-type="bibr">10</xref>). In the present study, it was revealed that LPS induced the activation of caspase-1 and also induced the expression of pyrin protein in pulmonary vascular ECs. The increase of pyrin protein expression may inhibit the activation of caspase-1 and form a negative feedback pathway. Notably, the increased expression of IL-10 induced by LPS in lung ECs may enhance the expression levels of pyrin in lung ECs and enhance the negative feedback regulation of inflammation. However, HS, by inhibiting the expression of IL-10, weakens the expression of pyrin, thereby damaging the negative feedback regulation of the inflammatory response and resulting in the enhancement of inflammatory body activation and consequently increasing the release of caspase-1.</p>
<p>The pyrin protein may inhibit the activation of caspase-1, and subsequently inhibit the maturation of inflammatory bodies. The destruction of the C terminal of the pyrin protein may enhance the sensitivity of mice to endotoxins and increase the activation of caspase-1, which indicates that the pyrin protein serves an important role in the maturation of inflammatory bodies (<xref rid="b19-etm-0-0-7757" ref-type="bibr">19</xref>). The pyrin protein interacts with caspase-1, apoptosis-associated speck-like protein containing a CARD, NLR family pyrin domain containing (NLRP)1, NLRP2, NLRP3 and IL-1B (precursors of inflammatory components) through its SPIa/ryanodine receptor and pyrin structural domains, thereby functioning as an inhibitor of the inflammatory body (<xref rid="b20-etm-0-0-7757" ref-type="bibr">20</xref>). A previous study has demonstrated that pyrin mutations may result in the activation of the NLRP3 independent inflammatory body, causing autoimmune diseases (<xref rid="b21-etm-0-0-7757" ref-type="bibr">21</xref>). The present study suggested that pyrin may result in different inflammatory outcomes through multiple different pathways.</p>
<p>IL-10 serves an important role in limiting inflammation and maintaining immune homeostasis (<xref rid="b22-etm-0-0-7757" ref-type="bibr">22</xref>). In acute respiratory distress syndrome, IL-10 has been demonstrated to inhibit proinflammatory mediators produced by pulmonary macrophages (<xref rid="b23-etm-0-0-7757" ref-type="bibr">23</xref>). In a previous clinical study, patients with acute respiratory distress syndrome, but with low levels of circulating and alveolar lavage fluid IL-10 exhibited an increased mortality rate compared with those with high IL-10 levels (<xref rid="b24-etm-0-0-7757" ref-type="bibr">24</xref>). At the gene level, a previous study indicated that, compared with pure LPS stimulation, hemorrhagic shock combined with LPS may significantly decrease the transcription of IL-10 mRNA (<xref rid="b25-etm-0-0-7757" ref-type="bibr">25</xref>). Patients that succumbed to mortality due to sepsis exhibited a decrease in IL-10 secretion (<xref rid="b26-etm-0-0-7757" ref-type="bibr">26</xref>), indicating that exogenous IL-10 had protective effects in sepsis or acute pancreatitis models (<xref rid="b26-etm-0-0-7757" ref-type="bibr">26</xref>,<xref rid="b27-etm-0-0-7757" ref-type="bibr">27</xref>). A limitation of the present study is the absence of an <italic>in vitro</italic> model. A previous study confirmed that an <italic>in vitro</italic> HS model inhibited the LPS-induced increase of IL-10 expression at the gene level, which is closely associated with the progression of HS-induced pulmonary inflammation (<xref rid="b28-etm-0-0-7757" ref-type="bibr">28</xref>). It has been suggested that pyrin may serve an inhibitory role in casepase-1 activation and inhibit the development of inflammation (<xref rid="b29-etm-0-0-7757" ref-type="bibr">29</xref>,<xref rid="b30-etm-0-0-7757" ref-type="bibr">30</xref>). In the present study, it was revealed that IL-10 may inhibit the activation of inflammatory cells by inducing the expression of pyrin in pulmonary vascular ECs. It was also confirmed that LPS induced the IL-10-based upregulated pyrin expression in lung ECs. The LPS treatment that induced pyrin protein expression in pulmonary vascular ECs was weakened by HS and LPS in the second &#x2018;hit&#x2019; model. However, exogenous IL-10 may reverse the inhibition of pyrin expression in HS. It was additionally confirmed that in pulmonary vascular ECs, IL-10 was able to inhibit HS in a rat model of LPS-induced caspase-1 activation in the lungs, and the data from the present study revealed that in pulmonary vascular ECs, the expression of IL-10 may induce pyrin, while decreasing the activation of the inflammasome, thereby serving an important role in lung injury that occurs subsequent to HS. Furthermore, the present study had certain limitations: In addition to those aforementioned, only exogenous IL-10 was used, and the results obtained were used to examine our hypothesis. Due to the lack of measurement of the other endogenous dynamic changes following HS in this experiment, the association between pyrin and endogenous IL-10 requires additional verification.</p>
<p>In conclusion, it was proposed that HS attenuated the LPS-induced pyrin expression in pulmonary vascular ECs and that HS may also damage the expression of IL-10, thereby decreasing the expression of the pyrin protein in pulmonary vascular ECs, resulting in the activation of caspase-1 following the second LPS &#x2018;hit&#x2019;. Additional studies investigating the expression changes and mechanism of pyrin in pulmonary vascular ECs are required to identify the underlying mechanism of SIRS induced by HS and novel targets for clinical intervention.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgements</title>
<p>Not applicable.</p>
</ack>
<sec>
<title>Funding</title>
<p>The present study was supported by the Zhejiang Provincial Natural Science Foundation of China (grant no., LY15H150005) and Medical Health Science and Technology Project of Zhejiang Provincial Health Commission (grant no., 2017KY176).</p>
</sec>
<sec>
<title>Availability of data and materials</title>
<p>The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.</p>
</sec>
<sec>
<title>Authors&#x0027; contributions</title>
<p>XJ and YY performed the majority of the experiments. XJ, YY and XL wrote the draft manuscript. XL also participated in the experimental design and helped aquire and analyze the experimental data. YY and PX designed and planned the implementation of the study. YX and SZ revised the manuscript, and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. All authors read and approved the final manuscript.</p>
</sec>
<sec>
<title>Ethics approval and consent to participate</title>
<p>The study was approved by the Medical Ethics Committee of Zhejiang Hospital.</p>
</sec>
<sec>
<title>Patient consent for publication</title>
<p>Not applicable.</p>
</sec>
<sec>
<title>Competing interests</title>
<p>The authors declare that they have no competing interests.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="b1-etm-0-0-7757"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El-Menyar</surname><given-names>A</given-names></name><name><surname>El-Thani</surname><given-names>A</given-names></name><name><surname>El Rasheid</surname><given-names>Z</given-names></name><name><surname>Ahmad</surname><given-names>Z</given-names></name><name><surname>Tuma</surname><given-names>M</given-names></name><name><surname>AbdulRahman</surname><given-names>H</given-names></name><name><surname>Parchani</surname><given-names>A</given-names></name><name><surname>Peralta</surname><given-names>R</given-names></name><name><surname>Latifi</surname><given-names>R</given-names></name></person-group><article-title>Multiple organ dysfunction syndrome (MODS): Is it preventable or inevitable</article-title><source>Int J Clin Med</source><volume>3</volume><fpage>722</fpage><lpage>730</lpage><year>2012</year><pub-id pub-id-type="doi">10.4236/ijcm.2012.37A127</pub-id></element-citation></ref>
<ref id="b2-etm-0-0-7757"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Wessem</surname><given-names>KJP</given-names></name><name><surname>Leenen</surname><given-names>LPH</given-names></name></person-group><article-title>Reduction in mortality rates of postinjury multiple organ dysfunction syndrome: A shifting paradigm? A prospective population-based cohort study</article-title><source>Shock</source><volume>49</volume><fpage>33</fpage><lpage>38</lpage><year>2018</year><pub-id pub-id-type="doi">10.1097/SHK.0000000000000938</pub-id><pub-id pub-id-type="pmid">28682941</pub-id></element-citation></ref>
<ref id="b3-etm-0-0-7757"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anne Morrison</surname><given-names>C</given-names></name><name><surname>Moran</surname><given-names>A</given-names></name><name><surname>Patel</surname><given-names>S</given-names></name><name><surname>Vidaurre Mdel</surname><given-names>P</given-names></name><name><surname>Carrick</surname><given-names>MM</given-names></name><name><surname>Tweardy</surname><given-names>DJ</given-names></name></person-group><article-title>Increased apoptosis of peripheral blood neutrophils is associated with reduced incidence of infection in trauma patients with hemorrhagic shock</article-title><source>J Infect</source><volume>66</volume><fpage>87</fpage><lpage>94</lpage><year>2013</year><pub-id pub-id-type="doi">10.1016/j.jinf.2012.10.001</pub-id><pub-id pub-id-type="pmid">23063873</pub-id></element-citation></ref>
<ref id="b4-etm-0-0-7757"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moore</surname><given-names>FA</given-names></name><name><surname>Sauaia</surname><given-names>A</given-names></name><name><surname>Moore</surname><given-names>EE</given-names></name><name><surname>Haenel</surname><given-names>JB</given-names></name><name><surname>Burch</surname><given-names>JM</given-names></name><name><surname>Lezotte</surname><given-names>DC</given-names></name></person-group><article-title>Postinjury multiple organ failure: A bimodal phenomenon</article-title><source>J Trauma</source><volume>40</volume><fpage>501</fpage><lpage>512</lpage><year>1996</year><pub-id pub-id-type="doi">10.1097/00005373-199604000-00001</pub-id><pub-id pub-id-type="pmid">8614027</pub-id></element-citation></ref>
<ref id="b5-etm-0-0-7757"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Minei</surname><given-names>JP</given-names></name><name><surname>Cuschieri</surname><given-names>J</given-names></name><name><surname>Sperry</surname><given-names>J</given-names></name><name><surname>Moore</surname><given-names>EE</given-names></name><name><surname>West</surname><given-names>MA</given-names></name><name><surname>Harbrecht</surname><given-names>BG</given-names></name><name><surname>O&#x0027;Keefe</surname><given-names>GE</given-names></name><name><surname>Cohen</surname><given-names>MJ</given-names></name><name><surname>Moldawer</surname><given-names>LL</given-names></name><name><surname>Tompkins</surname><given-names>RG</given-names></name><etal/></person-group><article-title>The changing pattern and implications of multiple organ failure after blunt injury with hemorrhagic shock</article-title><source>Crit Care Med</source><volume>40</volume><fpage>1129</fpage><lpage>1135</lpage><year>2012</year><pub-id pub-id-type="doi">10.1097/CCM.0b013e3182376e9f</pub-id><pub-id pub-id-type="pmid">22020243</pub-id></element-citation></ref>
<ref id="b6-etm-0-0-7757"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Xiang</surname><given-names>M</given-names></name><name><surname>Yuan</surname><given-names>Y</given-names></name><name><surname>Xiao</surname><given-names>G</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Jiang</surname><given-names>Y</given-names></name><name><surname>Vodovotz</surname><given-names>Y</given-names></name><name><surname>Billiar</surname><given-names>TR</given-names></name><name><surname>Wilson</surname><given-names>MA</given-names></name><name><surname>Fan</surname><given-names>J</given-names></name></person-group><article-title>Hemorrhagic shock augments lung endothelial cell activation: Role of temporal alterations of TLR4 and TLR2</article-title><source>Am J Physiol Regul Integr Comp Physiol</source><volume>297</volume><fpage>R1670</fpage><lpage>R1680</lpage><year>2009</year><pub-id pub-id-type="doi">10.1152/ajpregu.00445.2009</pub-id><pub-id pub-id-type="pmid">19828841</pub-id></element-citation></ref>
<ref id="b7-etm-0-0-7757"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chae</surname><given-names>JJ</given-names></name><name><surname>Wood</surname><given-names>G</given-names></name><name><surname>Richard</surname><given-names>K</given-names></name><name><surname>Jaffe</surname><given-names>H</given-names></name><name><surname>Colburn</surname><given-names>NT</given-names></name><name><surname>Masters</surname><given-names>SL</given-names></name><name><surname>Gumucio</surname><given-names>DL</given-names></name><name><surname>Shoham</surname><given-names>NG</given-names></name><name><surname>Kastner</surname><given-names>DL</given-names></name></person-group><article-title>The familial Mediterranean fever protein, pyrin, is cleaved by caspase-1 and activates NF-kappaB through its N-terminal fragment</article-title><source>Blood</source><volume>112</volume><fpage>1794</fpage><lpage>1803</lpage><year>2008</year><pub-id pub-id-type="doi">10.1182/blood-2008-01-134932</pub-id><pub-id pub-id-type="pmid">18577712</pub-id></element-citation></ref>
<ref id="b8-etm-0-0-7757"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chae</surname><given-names>JJ</given-names></name><name><surname>Komarow</surname><given-names>HD</given-names></name><name><surname>Cheng</surname><given-names>J</given-names></name><name><surname>Wood</surname><given-names>G</given-names></name><name><surname>Raben</surname><given-names>N</given-names></name><name><surname>Liu</surname><given-names>PP</given-names></name><name><surname>Kastner</surname><given-names>DL</given-names></name></person-group><article-title>Targeted disruption of pyrin, the FMF protein, causes heightened sensitivity to endotoxin and a defect in macrophage apoptosis</article-title><source>Mol Cell</source><volume>11</volume><fpage>591</fpage><lpage>604</lpage><year>2003</year><pub-id pub-id-type="doi">10.1016/S1097-2765(03)00056-X</pub-id><pub-id pub-id-type="pmid">12667444</pub-id></element-citation></ref>
<ref id="b9-etm-0-0-7757"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>X</given-names></name><name><surname>Qian</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Fan</surname><given-names>EK</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>L</given-names></name><name><surname>Billiar</surname><given-names>TR</given-names></name><name><surname>Wilson</surname><given-names>MA</given-names></name><name><surname>Shi</surname><given-names>X</given-names></name><name><surname>Fan</surname><given-names>J</given-names></name></person-group><article-title>TLR4-upregulated IL-1&#x03B2; and IL-1RI promote alveolar macrophage pyroptosis and lung inflammation through an autocrine mechanism</article-title><source>Sci Rep</source><volume>6</volume><fpage>31663</fpage><year>2016</year><pub-id pub-id-type="doi">10.1038/srep31663</pub-id><pub-id pub-id-type="pmid">27526865</pub-id></element-citation></ref>
<ref id="b10-etm-0-0-7757"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinon</surname><given-names>F</given-names></name><name><surname>Burns</surname><given-names>K</given-names></name><name><surname>Tschopp</surname><given-names>J</given-names></name></person-group><article-title>The inflammasome: A molecular platform triggering activation of inflammatory caspases and processing of proIL-beta</article-title><source>Mol Cell</source><volume>10</volume><fpage>417</fpage><lpage>426</lpage><year>2002</year><pub-id pub-id-type="doi">10.1016/S1097-2765(02)00599-3</pub-id><pub-id pub-id-type="pmid">12191486</pub-id></element-citation></ref>
<ref id="b11-etm-0-0-7757"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suzuki</surname><given-names>T</given-names></name><name><surname>Franchi</surname><given-names>L</given-names></name><name><surname>Toma</surname><given-names>C</given-names></name><name><surname>Ashida</surname><given-names>H</given-names></name><name><surname>Ogawa</surname><given-names>M</given-names></name><name><surname>Yoshikawa</surname><given-names>Y</given-names></name><name><surname>Mimuro</surname><given-names>H</given-names></name><name><surname>Inohara</surname><given-names>N</given-names></name><name><surname>Sasakawa</surname><given-names>C</given-names></name><name><surname>Nu&#x00F1;ez</surname><given-names>G</given-names></name></person-group><article-title>Differential regulation of caspase-1 activation, pyroptosis, and autophagy via Ipaf and ASC in Shigella-infected macrophages</article-title><source>PLoS Pathog</source><volume>3</volume><fpage>e111</fpage><year>2007</year><pub-id pub-id-type="doi">10.1371/journal.ppat.0030111</pub-id><pub-id pub-id-type="pmid">17696608</pub-id></element-citation></ref>
<ref id="b12-etm-0-0-7757"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Welborn</surname><given-names>BM</given-names><suffix>III</suffix></name><name><surname>Moldawer</surname><given-names>LL</given-names></name><name><surname>Seeger</surname><given-names>JM</given-names></name><name><surname>Minter</surname><given-names>RM</given-names></name><name><surname>Huber</surname><given-names>TS</given-names></name></person-group><article-title>Role of endogenous interleukin-10 in local and distant organ injury after visceral ischemia-reperfusion</article-title><source>Shock</source><volume>20</volume><fpage>35</fpage><lpage>40</lpage><year>2003</year><pub-id pub-id-type="doi">10.1097/01.SHK.0000071062.67193.b6</pub-id><pub-id pub-id-type="pmid">12813366</pub-id></element-citation></ref>
<ref id="b13-etm-0-0-7757"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Molthen</surname><given-names>RC</given-names></name></person-group><article-title>A simple, inexpensive, and effective light-carrying laryngoscopic blade for orotracheal intubation of rats</article-title><source>J Am Assoc Lab Anim Sci</source><volume>45</volume><fpage>88</fpage><lpage>93</lpage><year>2006</year><pub-id pub-id-type="pmid">16539342</pub-id></element-citation></ref>
<ref id="b14-etm-0-0-7757"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>X</given-names></name><name><surname>Hu</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Lin</surname><given-names>R</given-names></name><name><surname>Mao</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name></person-group><article-title>Gua Lou Gui Zhi decoction attenuates post-stroke spasticity via the modulation of GABAB receptors</article-title><source>Mol Med Rep</source><volume>12</volume><fpage>5957</fpage><lpage>5962</lpage><year>2015</year><pub-id pub-id-type="doi">10.3892/mmr.2015.4207</pub-id><pub-id pub-id-type="pmid">26260947</pub-id></element-citation></ref>
<ref id="b15-etm-0-0-7757"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>R</given-names></name><name><surname>Hu</surname><given-names>DY</given-names></name><name><surname>Liu</surname><given-names>LM</given-names></name><name><surname>Zhou</surname><given-names>XW</given-names></name></person-group><article-title>Protective effects of apocynin on &#x2018;two-hit&#x2019; injury induced by hemorrhagic shock and lipopolysaccharide</article-title><source>Acta Pharmacol Sin</source><volume>23</volume><fpage>1023</fpage><lpage>1028</lpage><year>2002</year><pub-id pub-id-type="pmid">12421480</pub-id></element-citation></ref>
<ref id="b16-etm-0-0-7757"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ulich</surname><given-names>TR</given-names></name><name><surname>Fann</surname><given-names>MJ</given-names></name><name><surname>Patterson</surname><given-names>PH</given-names></name><name><surname>Williams</surname><given-names>JH</given-names></name><name><surname>Samal</surname><given-names>B</given-names></name><name><surname>Del</surname><given-names>CJ</given-names></name><name><surname>Yin</surname><given-names>S</given-names></name><name><surname>Guo</surname><given-names>K</given-names></name><name><surname>Renick</surname><given-names>DG</given-names></name></person-group><article-title>Intratracheal injection of LPS and cytokines. V. LPS induces expression of LIF and LIF inhibits acute inflammation</article-title><source>Am J Physiol</source><volume>267</volume><fpage>L442</fpage><lpage>L446</lpage><year>1994</year><pub-id pub-id-type="pmid">7943346</pub-id></element-citation></ref>
<ref id="b17-etm-0-0-7757"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tawadros</surname><given-names>PS</given-names></name><name><surname>Powers</surname><given-names>KA</given-names></name><name><surname>Yang</surname><given-names>I</given-names></name><name><surname>Becker</surname><given-names>DA</given-names></name><name><surname>Ginsberg</surname><given-names>MD</given-names></name><name><surname>Szaszi</surname><given-names>K</given-names></name><name><surname>Kapus</surname><given-names>A</given-names></name><name><surname>Rotstein</surname><given-names>OD</given-names></name></person-group><article-title>Stilbazulenyl nitrone decreases oxidative stress and reduces lung injury after hemorrhagic shock/resuscitation and LPS</article-title><source>Antioxid Redox Signal</source><volume>9</volume><fpage>1971</fpage><lpage>1977</lpage><year>2007</year><pub-id pub-id-type="doi">10.1089/ars.2007.1765</pub-id><pub-id pub-id-type="pmid">17715998</pub-id></element-citation></ref>
<ref id="b18-etm-0-0-7757"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Testa</surname><given-names>JE</given-names></name><name><surname>Chrastina</surname><given-names>A</given-names></name><name><surname>Oh</surname><given-names>P</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Witkiewicz</surname><given-names>H</given-names></name><name><surname>Czarny</surname><given-names>M</given-names></name><name><surname>Buss</surname><given-names>T</given-names></name><name><surname>Schnitzer</surname><given-names>JE</given-names></name></person-group><article-title>Immunotargeting and cloning of two CD34 variants exhibiting restricted expression in adult rat endothelia in vivo</article-title><source>Am J Physiol Lung Cell Mol Physiol</source><volume>297</volume><fpage>L251</fpage><lpage>L262</lpage><year>2009</year><pub-id pub-id-type="doi">10.1152/ajplung.90565.2008</pub-id><pub-id pub-id-type="pmid">19465515</pub-id></element-citation></ref>
<ref id="b19-etm-0-0-7757"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feldmeyer</surname><given-names>L</given-names></name><name><surname>Keller</surname><given-names>M</given-names></name><name><surname>Niklaus</surname><given-names>G</given-names></name><name><surname>Hohl</surname><given-names>D</given-names></name><name><surname>Werner</surname><given-names>S</given-names></name><name><surname>Beer</surname><given-names>HD</given-names></name></person-group><article-title>The inflammasome mediates UVB-induced activation and secretion of interleukin-1beta by keratinocytes</article-title><source>Curr Biol</source><volume>17</volume><fpage>1140</fpage><lpage>1145</lpage><year>2007</year><pub-id pub-id-type="doi">10.1016/j.cub.2007.05.074</pub-id><pub-id pub-id-type="pmid">17600714</pub-id></element-citation></ref>
<ref id="b20-etm-0-0-7757"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinon</surname><given-names>F</given-names></name><name><surname>Hofmann</surname><given-names>K</given-names></name><name><surname>Tschopp</surname><given-names>J</given-names></name></person-group><article-title>The pyrin domain: A possible member of the death domain-fold family implicated in apoptosis and inflammation</article-title><source>Curr Biol</source><volume>11</volume><fpage>R118</fpage><lpage>R120</lpage><year>2001</year><pub-id pub-id-type="doi">10.1016/S0960-9822(01)00056-2</pub-id><pub-id pub-id-type="pmid">11250163</pub-id></element-citation></ref>
<ref id="b21-etm-0-0-7757"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chae</surname><given-names>J</given-names></name><name><surname>Cho</surname><given-names>YH</given-names></name><name><surname>Lee</surname><given-names>GS</given-names></name><name><surname>Cheng</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>PP</given-names></name><name><surname>Feigenbaum</surname><given-names>L</given-names></name><name><surname>Katz</surname><given-names>SI</given-names></name><name><surname>Kastner</surname><given-names>DL</given-names></name></person-group><article-title>Gain-of-function Pyrin mutations induce NLRP3 protein-independent interleukin-1&#x03B2; activation and severe autoinflammation in mice</article-title><source>Immunity</source><volume>34</volume><fpage>755</fpage><lpage>768</lpage><year>2011</year><pub-id pub-id-type="doi">10.1016/j.immuni.2011.02.020</pub-id><pub-id pub-id-type="pmid">21600797</pub-id></element-citation></ref>
<ref id="b22-etm-0-0-7757"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iyer</surname><given-names>SS</given-names></name><name><surname>Cheng</surname><given-names>G</given-names></name></person-group><article-title>Role of interleukin 10 transcriptional regulation in inflammation and autoimmune disease</article-title><source>Crit Rev Immunol</source><volume>32</volume><fpage>23</fpage><lpage>63</lpage><year>2012</year><pub-id pub-id-type="doi">10.1615/CritRevImmunol.v32.i1.30</pub-id><pub-id pub-id-type="pmid">22428854</pub-id></element-citation></ref>
<ref id="b23-etm-0-0-7757"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lo</surname><given-names>C</given-names></name><name><surname>Fu</surname><given-names>M</given-names></name><name><surname>Cryer</surname><given-names>HG</given-names></name></person-group><article-title>Interleukin 10 inhibits alveolar macrophage production of inflammatory mediators involved in adult respiratory distress syndrome</article-title><source>J Surg Res</source><volume>79</volume><fpage>179</fpage><lpage>184</lpage><year>1998</year><pub-id pub-id-type="doi">10.1006/jsre.1998.5418</pub-id><pub-id pub-id-type="pmid">9758735</pub-id></element-citation></ref>
<ref id="b24-etm-0-0-7757"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Armstrong</surname><given-names>L</given-names></name><name><surname>Millar</surname><given-names>AB</given-names></name></person-group><article-title>Relative production of tumour necrosis factor alpha and interleukin 10 in adult respiratory distress syndrome</article-title><source>Thorax</source><volume>52</volume><fpage>442</fpage><lpage>446</lpage><year>1997</year><pub-id pub-id-type="doi">10.1136/thx.52.5.442</pub-id><pub-id pub-id-type="pmid">9176536</pub-id></element-citation></ref>
<ref id="b25-etm-0-0-7757"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khadaroo</surname><given-names>RG</given-names></name><name><surname>Fan</surname><given-names>J</given-names></name><name><surname>Powers</surname><given-names>KA</given-names></name><name><surname>Fann</surname><given-names>B</given-names></name><name><surname>Kapus</surname><given-names>A</given-names></name><name><surname>Rotstein</surname><given-names>OD</given-names></name></person-group><article-title>Impaired induction of IL-10 expression in the lung following hemorrhagic shock</article-title><source>Shock</source><volume>22</volume><fpage>333</fpage><lpage>339</lpage><year>2004</year><pub-id pub-id-type="doi">10.1097/01.shk.0000136095.96306.08</pub-id><pub-id pub-id-type="pmid">15377888</pub-id></element-citation></ref>
<ref id="b26-etm-0-0-7757"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yeh</surname><given-names>FL</given-names></name><name><surname>Shen</surname><given-names>HD</given-names></name><name><surname>Fang</surname><given-names>RH</given-names></name></person-group><article-title>Deficient transforming growth factor beta and interleukin-10 responses contribute to the septic death of burned patients</article-title><source>Burns</source><volume>28</volume><fpage>631</fpage><lpage>637</lpage><year>2002</year><pub-id pub-id-type="doi">10.1016/S0305-4179(02)00113-4</pub-id><pub-id pub-id-type="pmid">12417156</pub-id></element-citation></ref>
<ref id="b27-etm-0-0-7757"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kusske</surname><given-names>AM</given-names></name><name><surname>Rongione</surname><given-names>AJ</given-names></name><name><surname>Ashley</surname><given-names>SW</given-names></name><name><surname>McFadden</surname><given-names>DW</given-names></name><name><surname>Reber</surname><given-names>HA</given-names></name></person-group><article-title>Interleukin-10 prevents death in lethal necrotizing pancreatitis in mice</article-title><source>Surgery</source><volume>120</volume><fpage>284</fpage><lpage>289</lpage><year>1996</year><pub-id pub-id-type="doi">10.1016/S0039-6060(96)80299-6</pub-id><pub-id pub-id-type="pmid">8751594</pub-id></element-citation></ref>
<ref id="b28-etm-0-0-7757"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cruz</surname><given-names>CM</given-names></name><name><surname>Rinna</surname><given-names>A</given-names></name><name><surname>Forman</surname><given-names>HJ</given-names></name><name><surname>Ventura</surname><given-names>AL</given-names></name><name><surname>Persechini</surname><given-names>PM</given-names></name><name><surname>Ojcius</surname><given-names>DM</given-names></name></person-group><article-title>ATP activates a reactive oxygen species-dependent oxidative stress response and secretion of proinflammatory cytokines in macrophages</article-title><source>J Biol Chem</source><volume>282</volume><fpage>2871</fpage><lpage>2879</lpage><year>2007</year><pub-id pub-id-type="doi">10.1074/jbc.M608083200</pub-id><pub-id pub-id-type="pmid">17132626</pub-id></element-citation></ref>
<ref id="b29-etm-0-0-7757"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Halle</surname><given-names>A</given-names></name><name><surname>Hornung</surname><given-names>V</given-names></name><name><surname>Petzold</surname><given-names>GC</given-names></name><name><surname>Stewart</surname><given-names>CR</given-names></name><name><surname>Monks</surname><given-names>BG</given-names></name><name><surname>Reinheckel</surname><given-names>T</given-names></name><name><surname>Fitzgerald</surname><given-names>KA</given-names></name><name><surname>Latz</surname><given-names>E</given-names></name><name><surname>Moore</surname><given-names>KJ</given-names></name><name><surname>Golenbock</surname><given-names>DT</given-names></name></person-group><article-title>The NALP3 inflammasome is involved in the innate immune response to amyloid-beta</article-title><source>Nat Immunol</source><volume>9</volume><fpage>857</fpage><lpage>865</lpage><year>2008</year><pub-id pub-id-type="doi">10.1038/ni.1636</pub-id><pub-id pub-id-type="pmid">18604209</pub-id></element-citation></ref>
<ref id="b30-etm-0-0-7757"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watanabe</surname><given-names>H</given-names></name><name><surname>Gaide</surname><given-names>O</given-names></name><name><surname>P&#x00E9;trilli</surname><given-names>V</given-names></name><name><surname>Martinon</surname><given-names>F</given-names></name><name><surname>Contassot</surname><given-names>E</given-names></name><name><surname>Roques</surname><given-names>S</given-names></name><name><surname>Kummer</surname><given-names>JA</given-names></name><name><surname>Tschopp</surname><given-names>J</given-names></name><name><surname>French</surname><given-names>LE</given-names></name></person-group><article-title>Activation of the IL-1beta-processing inflammasome is involved in contact hypersensitivity</article-title><source>J Invest Dermatol</source><volume>127</volume><fpage>1956</fpage><lpage>1963</lpage><year>2007</year><pub-id pub-id-type="doi">10.1038/sj.jid.5700819</pub-id><pub-id pub-id-type="pmid">17429439</pub-id></element-citation></ref>
</ref-list>
</back>
<floats-group>
<fig id="f1-etm-0-0-7757" position="float">
<label>Figure 1.</label>
<caption><p>HS attenuates the LPS-induced pyrin expression in pulmonary vascular ECs. Immunofluorescence staining analysis was conducted. Pulmonary vascular endothelial cells (white arrows) were incubated with anti-CD34 and anti-pyrin antibodies. The CD34-positive cells (red) presented a typical cobblestone-like morphology. The merged images (yellow) demonstrate overlap of pyrin (green) and CD34 (red). Magnfication, &#x00D7;200. SM, sham operation; SAL, tracheal injection of saline; HS, hemorrhagic shock; LPS, tracheal injection of lipopolysaccharide. CD34, cluster of differentiation 34.</p></caption>
<graphic xlink:href="etm-18-03-1768-g00.tif"/>
</fig>
<fig id="f2-etm-0-0-7757" position="float">
<label>Figure 2.</label>
<caption><p>HS leads to a downregulation and upregulation LPS-induced pyrin and caspase-1 expression, respectively, in pulmonary vascular ECs. Western blot analysis was conducted. Expression changes of (A) pyrin and (B) caspase-1 following HS-LPS &#x2018;hit&#x2019;. &#x002A;P&#x003C;0.05 vs. the SM &#x002B; SAL group. <sup>#</sup>P&#x003C;0.05 vs. the HS &#x002B; SAL group. <sup>&#x0394;</sup>P&#x003C;0.05 vs. the SM &#x002B; LPS group (n=6). SM, sham operation; SAL, tracheal injection of saline; HS, hemorrhagic shock; LPS, tracheal injection of lipopolysaccharide.</p></caption>
<graphic xlink:href="etm-18-03-1768-g01.tif"/>
</fig>
<fig id="f3-etm-0-0-7757" position="float">
<label>Figure 3.</label>
<caption><p>Involvement of IL-10 in regulating pyrin expression changes in pulmonary vascular ECs following the second &#x2018;hit&#x2019; of HS-LPS. Western blot analysis was conducted. (A) Expression changes of pyrin following HS-LPS &#x2018;hit&#x2019; and exogenous recombinant IL-10 treatment. &#x002A;P&#x003C;0.05 vs. HS &#x002B; LPS group. <sup>#</sup>P&#x003C;0.05 vs. HS &#x002B; LPS group. <sup>&#x0394;</sup>P&#x003C;0.05 vs. HS &#x002B; LPS &#x002B; NS group (n=6). (B) Expression changes of caspase-1 following HS-LPS &#x2018;hit&#x2019; and exogenous recombinant IL-10 treatment. &#x002A;P&#x003C;0.05 vs. SM &#x002B; LPS group. <sup>#</sup>P&#x003C;0.05 vs. HS &#x002B; LPS group. <sup>&#x0394;</sup>P&#x003C;0.05 vs. HS &#x002B; LPS &#x002B; NS group (n=6). SM, sham operation; NS, intratracheal injection of saline; HS, hemorrhagic shock; LPS, tracheal injection of lipopolysaccharide; IL-10, interleukin-10.</p></caption>
<graphic xlink:href="etm-18-03-1768-g02.tif"/>
</fig>
</floats-group>
</article>
